CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

Junshik Hong; Sanghui Park; Jinny Park; Seung Jun Jang; Hee Kyung Ahn; Sun Jin Sym; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee

doi:10.1007/s00277-012-1533-z

CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

Junshik Hong, Sanghui Park, Jinny Park, Seung Jun Jang, Hee Kyung Ahn, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee

Department of Pathology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/ CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non- GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non- GCB subgroup (p=0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99? patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p=0.004) and 2-year OS (p00.003) were observed in patients with GCB/CD99+ and non-GCB/ CD99? compared to the others, and the combination classification was found to be an independent prognostic factor.

Original language	English
Pages (from-to)	1897-1906
Number of pages	10
Journal	Annals of Hematology
Volume	91
Issue number	12
DOIs	https://doi.org/10.1007/s00277-012-1533-z
State	Published - Dec 2012

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the Ewha Womans University Research Grant of 2012.

Keywords

CD99
Diffuse large B-cell lymphoma
Immunohistochemistry
Prognosis

Access to Document

10.1007/s00277-012-1533-z

Cite this

@article{7d2201c48f9b4522bc412ece79e7d169,

title = "CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy",

abstract = "In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/ CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non- GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non- GCB subgroup (p=0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99? patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p=0.004) and 2-year OS (p00.003) were observed in patients with GCB/CD99+ and non-GCB/ CD99? compared to the others, and the combination classification was found to be an independent prognostic factor.",

keywords = "CD99, Diffuse large B-cell lymphoma, Immunohistochemistry, Prognosis",

author = "Junshik Hong and Sanghui Park and Jinny Park and Jang, {Seung Jun} and Ahn, {Hee Kyung} and Sym, {Sun Jin} and Cho, {Eun Kyung} and Shin, {Dong Bok} and Lee, {Jae Hoon}",

note = "Funding Information: Acknowledgments This work was supported by the Ewha Womans University Research Grant of 2012.",

year = "2012",

month = dec,

doi = "10.1007/s00277-012-1533-z",

language = "English",

volume = "91",

pages = "1897--1906",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

AU - Hong, Junshik

AU - Park, Sanghui

AU - Park, Jinny

AU - Jang, Seung Jun

AU - Ahn, Hee Kyung

AU - Sym, Sun Jin

AU - Cho, Eun Kyung

AU - Shin, Dong Bok

AU - Lee, Jae Hoon

N1 - Funding Information: Acknowledgments This work was supported by the Ewha Womans University Research Grant of 2012.

PY - 2012/12

Y1 - 2012/12

N2 - In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/ CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non- GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non- GCB subgroup (p=0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99? patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p=0.004) and 2-year OS (p00.003) were observed in patients with GCB/CD99+ and non-GCB/ CD99? compared to the others, and the combination classification was found to be an independent prognostic factor.

AB - In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/ CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non- GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non- GCB subgroup (p=0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99? patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p=0.004) and 2-year OS (p00.003) were observed in patients with GCB/CD99+ and non-GCB/ CD99? compared to the others, and the combination classification was found to be an independent prognostic factor.

KW - CD99

KW - Diffuse large B-cell lymphoma

KW - Immunohistochemistry

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84870996651&partnerID=8YFLogxK

U2 - 10.1007/s00277-012-1533-z

DO - 10.1007/s00277-012-1533-z

M3 - Article

C2 - 22864685

AN - SCOPUS:84870996651

SN - 0939-5555

VL - 91

SP - 1897

EP - 1906

JO - Annals of Hematology

JF - Annals of Hematology

IS - 12

ER -

CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this